Source: Sun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera™ (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. Seciera™ is a patented, novel, proprietary nanomicellar formulation of cyclosporine A 0.09%. It is a clear, preservative-free, aqueous solution. Seciera™ is being developed by Ocular…...
FDA approves Pfizer ointment for itchy skin condition
Source: Reuters The U.S. Food and Drug Administration on Wednesday said it approved Pfizer Inc's (PFE.N) ointment to treat mild to moderate cases of the itchy skin condition eczema, or atopic dermatitis, for use in patients aged two years and older. Atopic dermatitis is the most common of the many…...
Valeant Appoints William D. Humphries As EVP, Dermatology
Source: PR Newswire Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that William D. Humphries has been appointed Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to Joseph C. Papa, Valeant's Chairman and Chief…...
Aclaris starts phase 1 trial for ATI-50001 to treat alopecia totalis and alopecia universalis
Source: Aclaris Therapeutics' investigational new drug (IND) application for ATI-50001, an orally administered investigational Janus Kinase (JAK) inhibitor, for the potential treatment of alopecia totalis and alopecia universalis has cleared the 30-day review period by the US Food and Drug Administration, allowing the company to go ahead with its planned…...
Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
Source: Globe Newswire Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced top-line results from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV. The highest dose tested, SB206 12%, demonstrated a statistically significant improvement (p<0.05) in the incidence…...
Novartis, Celgene and Pfizer trot out positive data in red-hot psoriatic arthritis race
Source: Novartis’ Cosentyx and Celgene’s Otezla aren’t just battling it out in the psoriasis arena. As of early this year, they’re competing in psoriatic arthritis, too—and each drugmaker made its case this week with new data in that disease. Cosentyx can steadily improve the signs and symptoms of psoriatic arthritis—including…...
Valeant Shares Plunge as It Slashes Guidance Again
Source: The Wall Street Journal Valeant Pharmaceuticals International Inc. cut its annual outlook again Tuesday as the drug company, struggling to remake its business after a series of missteps, signaled its turnaround may take longer than expected. Shares of the company tumbled 25% to $14.42, the stock’s lowest point in…...
QFR Solutions Earns LinkedIn’s Top Specialist Firm
Source: LinkedIn Thank you to our Elite Talent Network!! QFR Solutions has earned the Top spot (#1) in LinkedIn’s Top 25 of LinkedIn’s Most Socially Engaged Staffing Agencies 2016. There were 60,000 staffing firms considered with 57,000 of these being in our category of Specialist / Boutique firms. Listed below…...
Myovant bumps IPO to $218M with Pfizer, BB Biotech aid
Source: FierceBiotech Biotech IPOs are faring well this fall. That’s despite tough talk from U.S. politicians on biopharma pricing, as the topic has become a focal point in the presidential elections. In a second IPO of the week, Myovant Sciences ($MYOV) raised a larger-than-expected offering after it priced at the…...
Allergan recalls some Tazorac acne gel
Source: Allergan, which made its name with dermatology products like Botox, recalled more than 42,000 tubes of an acne gel that failed to meet specifications during stability testing. According to the most recent FDA Enforcement Report, Allergan recalled 42,359 tubes of Tazorac in 30-g and 100-g sizes because the gel…...